Aurobindo Pharma Gets US OK To Sell Generic Heartburn Syrup

BANGALORE (Dow Jones)--Aurobindo Pharma Ltd. (524804.BY) Monday said it has received a final approval from the U.S Food and Drug Administration to sell a generic version of GlaxoSmithKline PLC's (GSK) Zantac syrup for treating heartburn. Aurobindo Pharma is ready to start selling ranitidine hydrochloride syrup--the generic version of Zantac--in a strength of 15 milligram per milliliter, the Indian generic drugmaker said. Zantac has annual U.S. sales of about $40 million, the company said, citing IMS Health market research data. -By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com (END) Dow Jones Newswires August 02, 2010 01:09 ET (05:09 GMT)